[HTML][HTML] Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
[PDF][PDF] Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
L Liu, RG Casner, Y Guo, Q Wang, S Iketani… - Immunity, 2023 - scienceopen.com
SUMMARY SARS-CoV-2 continues to evolve, with many variants evading clinically
authorized antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing …
authorized antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing …
[HTML][HTML] Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
L Liu, RG Casner, Y Guo, Q Wang, S Iketani, JFW Chan… - Immunity, 2023 - Elsevier
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
[HTML][HTML] Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
L Liu, RG Casner, Y Guo, Q Wang, S Iketani, JFW Chan… - Immunity, 2023 - ncbi.nlm.nih.gov
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking.
L Liu, RG Casner, Y Guo, Q Wang, S Iketani, JF Chan… - Immunity, 2023 - europepmc.org
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
L Liu, RG Casner, Y Guo, Q Wang, S Iketani… - …, 2023 - pubmed.ncbi.nlm.nih.gov
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking.
L Liu, RG Casner, Y Guo, Q Wang, S Iketani, JF Chan… - Immunity, 2023 - europepmc.org
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …